Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have been assigned a consensus broker rating score of 2.50 (Hold) from the two analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a buy rating on the company. Aevi Genomic Medicine’s rating score has declined by 42.9% in the last three months as a result of various analysts’ upgrades and downgrades.

Brokers have set a twelve-month consensus price objective of $5.17 for the company and are predicting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also given Aevi Genomic Medicine an industry rank of 234 out of 265 based on the ratings given to related companies.

Several research analysts recently issued reports on the company. Jefferies Group reissued a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th. Needham & Company LLC dropped their price objective on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, August 16th.

Aevi Genomic Medicine (GNMX) traded up $0.02 on Tuesday, hitting $1.27. The stock had a trading volume of 158,333 shares, compared to its average volume of 478,132. Aevi Genomic Medicine has a 1 year low of $0.98 and a 1 year high of $6.89.

Aevi Genomic Medicine (NASDAQ:GNMX) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). During the same quarter in the previous year, the company earned ($0.29) earnings per share. sell-side analysts forecast that Aevi Genomic Medicine will post -0.88 EPS for the current year.

In related news, insider Garry Arthur Neil bought 75,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were acquired at an average price of $1.26 per share, with a total value of $94,500.00. Following the transaction, the insider now owns 114,774 shares of the company’s stock, valued at $144,615.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael F. Cola bought 119,047 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $149,999.22. Following the transaction, the chief executive officer now directly owns 218,483 shares in the company, valued at approximately $275,288.58. The disclosure for this purchase can be found here. In the last three months, insiders purchased 615,079 shares of company stock worth $775,000. 15.20% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in GNMX. Northern Capital Management LLC boosted its position in Aevi Genomic Medicine by 317.9% during the 2nd quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 80,675 shares in the last quarter. LMR Partners LLP bought a new stake in Aevi Genomic Medicine during the 2nd quarter valued at $149,000. Wells Fargo & Company MN boosted its position in Aevi Genomic Medicine by 433.7% during the 3rd quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 106,178 shares in the last quarter. Birchview Capital LP boosted its position in Aevi Genomic Medicine by 88.2% during the 2nd quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 60,000 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Aevi Genomic Medicine by 16.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 13,966 shares in the last quarter. 16.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Post ($0.17) EPS” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/analysts-expect-aevi-genomic-medicine-inc-gnmx-to-post-0-17-eps.html.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.